Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Acetaminophen+butalbital+caffeine 325mg/50mg/40mg capsule |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Acetaminophen+butalbital+caffeine 500mg/50mg/40mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Acetaminophen+butalbital+caffeine 500mg/50mg/40mg tablet |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Acetaminophen+butalbital+caffeine 325mg/50mg/40mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Acetaminophen+butalbital+caffeine 325mg/50mg/40mg capsule |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Caffeine 65 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 65 mg and paracetamol 500 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Acetaminophen+butalbital+caffeine 500mg/50mg/40mg tablet |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin + butalbital + caffeine 325mg/50mg/40mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin + butalbital + caffeine 325mg/50mg/40mg tablet |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Caffeine monohydrate (substance) |
Is a |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Caffeine hydrate (substance) |
Is a |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Management of caffeine intake |
Direct substance |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine citrate (substance) |
Is modification of (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Caffeinated coffee |
Is modification of (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Caffeine hydrate (substance) |
Is modification of (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Caffeine monohydrate (substance) |
Is modification of (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Caffeinated soft drinks |
Is modification of (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing caffeine and codeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing caffeine and codeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Acetaminophen 300 mg and caffeine 15 mg and codeine phosphate 30 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Caffeine- and sodium benzoate-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Ergotamine tartrate+caffeine 2mg/100mg suppository (substance) |
Has basis of strength substance (attribute) |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Ergotamine tartrate+caffeine 2mg/100mg suppository (substance) |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing caffeine and ergotamine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing aspirin and caffeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing aspirin and butalbital and caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing aspirin and butalbital and caffeine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing aspirin and caffeine and orphenadrine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin- and caffeine- and dihydrocodeine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing aspirin and caffeine and dihydrocodeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin- and butalbital- and caffeine- and codeine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin + butalbital + caffeine 325mg/50mg/40mg tablet |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 770 milligram and caffeine 60 milligram and orphenadrine citrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine 25 mg and paracetamol 450 mg oral tablet |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Acetaminophen 300 mg and caffeine 15 mg and codeine phosphate 30 mg oral tablet |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Caffeine 65 mg and paracetamol 500 mg oral tablet |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has precise active ingredient |
False |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Acetaminophen+butalbital+caffeine 500mg/50mg/40mg tablet |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing butalbital and caffeine and codeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing butalbital and caffeine and codeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing caffeine and dihydrocodeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Acetaminophen+butalbital+caffeine 325mg/50mg/40mg capsule |
Has precise active ingredient |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing caffeine and isometheptene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin- and caffeine- and dextropropoxyphene-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing butalbital and caffeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine- and ergotamine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Caffeine- and paracetamol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing aspirin and caffeine and dextropropoxyphene (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |